The focus of our research in recent years has been in mesothelioma and lung cancer. In mesothelioma, we have been examining genomic data of patients treated by the immune checkpoint blockade therapy to find signatures of responders. In lung cancer, we have been analyzing genomic profiles and immune micro-environment of SCLC tumors from long term and exceptional survivors and are aiming to incorporate our findings in developing effective therapies. Also, we have been investigating therapeutic vulnerabilities of lung adenocarcinoma with elevated ASCL1 expression through bioinformatics and basic research including pathways involving EGFR and RET oncogenes.

Ms. Hely Ollila is a fourth-year medical student (B.M.) and a Ph.D. student from the University of Helsinki, Finland. In her research, Ms. Ollila studies the prognostic features of immunological and stromal tumor microenvironment in malignant pleural mesothelioma (MPM). Ms. Ollila has special expertise in fluorescence multiplex immunohistochemistry technique which enables simultaneous detection of multiple antigens in one tissue sample, and therefore a thorough spatial characterization of the different cell types forming the MPM tumor microenvironment.